NOVO NORDISK A/S |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 907 DKK | -0.64% |
|
-0.37% | +29.85% |
| 16/05 | Health Care Flat as Momentum Wanes -- Health Care Roundup | DJ |
| 16/05 | Novo Nordisk Reports Fire Incident at Under-Construction Facility in Kalundborg, Denmark | MT |
Presentation Operator MessageOperator (Operator)Welcome to the Q3 2021 Novo Nordisk A/S earnin...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
07/08/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
912.9
DKK
Average target price
909.2
DKK
Spread / Average Target
-0.40%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +29.85% | 59TCr | |
| +32.36% | 69TCr | |
| -1.60% | 37TCr | |
| +20.07% | 33TCr | |
| +6.04% | 29TCr | |
| +14.66% | 24TCr | |
| -3.39% | 21TCr | |
| +10.25% | 21TCr | |
| +9.27% | 17TCr | |
| +0.45% | 16TCr |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Transcript : Novo Nordisk A/S, Nine Months 2021 Earnings Call, Nov 03, 2021